Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Amgen, Servier Form Heart Drug Deal
by Lisa M. Jarvis
July 15, 2013
| A version of this story appeared in
Volume 91, Issue 28
Amgen will pay the French drug firm Servier $50 million up front for the U.S. rights to ivabradine, an If channel inhibitor approved in Europe to lower heart rates in people with chronic heart failure and stable angina. The companies have also swapped rights for certain heart drugs in development. Amgen gains an option for U.S. development of Servier’s S38844, now in Phase II studies to treat heart failure. Servier, meanwhile, gets European rights to Amgen’s omecamtiv mecarbil, a cardiac myosin activator in Phase II studies to improve heart function in people with systolic dysfunction.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter